Results 211 to 220 of about 413,499 (385)
Socio‐economic status and the effect of guideline‐directed medical therapy in the STRONG‐HF study
Abstract Aims Acute heart failure (AHF) impacts millions globally, with outcomes varying based on socio‐economic status (SES). Methods SES measured by annual household income, years of education and medical insurance coverage. Each patient's income and education level relative to the median or mean, respectively, in the country was calculated, and ...
Albertino Damasceno+29 more
wiley +1 more source
Natural Course of Peripartum Cardiomyopathy [PDF]
John G. Demakis+6 more
openalex +1 more source
Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. [PDF]
Barry J. Maron, William C. Roberts
openalex +1 more source
Vincent Y. See, Libin Wang
doaj +1 more source
Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. [PDF]
Douglas R. Rosing+3 more
openalex +1 more source
Increased risk of cardiomyopathy in individuals with methamphetamine related disorders in Taiwan. [PDF]
Yu PC+10 more
europepmc +1 more source
Defective in vitro suppressor cell function in idiopathic congestive cardiomyopathy. [PDF]
R E Fowles, C P Bieber, E. B. Stinson
openalex +1 more source
Abstract Aims The last released European guidelines on the management of heart failure (HF) recommend in patients with chronic HF with reduced ejection fraction (HFrEF) a pharmacological approach based on four fundamental drugs to be rapidly implemented and then uptitrated to modify disease progression.
Stefania Paolillo+62 more
wiley +1 more source
Age at onset and clinical course of RBM20-mediated cardiomyopathy. [PDF]
Garmany R+7 more
europepmc +1 more source
Abstract Aims No curative treatment is available for RASopathy‐associated childhood‐onset hypertrophic cardiomyopathy (RAS‐CM). Preclinical data and individual reports suggest a beneficial effect of small molecules targeting the RAS–mitogen‐activated protein (MAP) kinase (MAPK) pathway in severely affected RAS‐CM patients.
Jules Hamers+11 more
wiley +1 more source